What is the recommended management for a patient with immune thrombocytopenia on mycophenolate mofetil and prednisolone who is hospitalized with influenza?

Management of ITP Patient on MMF and Prednisolone Hospitalized with Influenza

Continue both mycophenolate mofetil and prednisolone at current doses while treating the influenza infection with antivirals, and monitor platelet counts closely during hospitalization.

Immediate Management Priorities

Continue Immunosuppression

• Do not discontinue MMF or prednisolone during acute influenza infection 1
• These medications are maintaining platelet counts and preventing ITP relapse
• Abrupt withdrawal risks severe thrombocytopenia and bleeding complications
• MMF dosing should remain at standard ITP doses (typically 1g twice daily) unless neutropenia develops (ANC < 1.3 × 10³/µL) 1

Antiviral Treatment

• Initiate neuraminidase inhibitors (oseltamivir or zanamivir) immediately upon diagnosis 2
• Early antiviral therapy is critical for immunosuppressed patients
• Do not delay treatment waiting for confirmatory testing

Antibiotic Coverage

• Start empirical antibiotics promptly (within 4 hours of admission) if bacterial superinfection is suspected 2
• For non-severe pneumonia: oral co-amoxiclav or tetracycline 2
• For severe pneumonia: IV co-amoxiclav or 2nd/3rd generation cephalosporin PLUS macrolide (clarithromycin/erythromycin) 2
• This covers S. pneumoniae and S. aureus, the predominant pathogens in influenza-related bacterial pneumonia

Key Monitoring Parameters

Hematologic Surveillance

• Check complete blood counts daily during acute illness 1
• Watch for neutropenia (ANC < 1.3 × 10³/µL), which requires MMF dose reduction or interruption 1
• Monitor platelet counts for ITP flare (target >30 × 10⁹/L to avoid bleeding risk) 3
• Assess for signs of bleeding (petechiae, purpura, mucosal bleeding)

Infection Monitoring

• Immunosuppressed patients on MMF have increased risk of opportunistic infections 1
• Monitor for herpes virus reactivation (HSV, VZV, CMV) which occurs more frequently with MMF 1
• Watch for fungal superinfections

Critical Drug Interaction Considerations

Avoid Specific Antibiotic Combinations

• Do not use norfloxacin plus metronidazole together - this combination reduces MPA exposure by 33% and may precipitate ITP relapse 1
• Ciprofloxacin and amoxicillin-clavulanate can reduce MMF levels by approximately 50% within 3 days 1
• If these antibiotics are necessary, consider increasing MMF monitoring and potentially adjusting doses

Antacid Precautions

• Avoid magnesium/aluminum hydroxide antacids - they reduce MMF absorption by 33% (Cmax) and 17% (AUC) 1
• Use alternative acid suppression if needed

MMF-Specific Considerations in This Context

Impaired Vaccine Response

• MMF profoundly suppresses humoral immune responses 4
• This patient likely had poor antibody response to any prior influenza vaccination
• Natural infection may also generate suboptimal immunity
• Consider this for future vaccination planning (though current infection makes this moot)

Infection Risk Profile

• MMF increases susceptibility to viral infections, particularly herpes viruses 1
• The combination of MMF plus prednisolone creates additive immunosuppression
• However, the risk of stopping these medications and causing ITP crisis outweighs infection concerns in the acute setting

When to Adjust Immunosuppression

Reduce or Hold MMF if:

• Neutropenia develops (ANC < 1.3 × 10³/µL) 1
• Severe, life-threatening infection with septic shock
• Patient requires mechanical ventilation with multi-organ failure

Maintain Current Doses if:

• Platelet count remains stable (>30 × 10⁹/L)
• No neutropenia
• Infection is controlled with antivirals/antibiotics
• Patient is clinically stable

Common Pitfalls to Avoid

1. Do not reflexively stop immunosuppression - the ITP will likely flare, creating a bleeding risk that compounds the clinical situation
2. Do not use live attenuated influenza vaccine in future - contraindicated with MMF 1
3. Do not assume influenza alone - bacterial superinfection occurs frequently and requires prompt antibiotic coverage 2
4. Do not use certain antibiotic combinations that reduce MMF levels significantly 1

Discharge Planning

• Resume normal MMF dosing schedule if temporarily adjusted
• Counsel on infection prevention strategies
• Consider inactivated influenza vaccine for next season (though response will be blunted) 4
• Ensure close hematology follow-up within 1-2 weeks post-discharge